Thrombolysis in acute ischaemic stroke - time for a rethink? episode artwork

EPISODE · Mar 18, 2015 · 16 MIN

Thrombolysis in acute ischaemic stroke - time for a rethink?

from Medicine and Science from The BMJ · host The BMJ

In the US the licence, or marketing authorisation, for alteplase is limited to 0-3 hours after onset of stroke, but some other countries - including the UK and Australia - have extended the licence to 4.5 hours. In an analysis article on thebmj.com Brian Alper, vice president of evidence based medicine research and development at Dynamed, and colleagues, interpret the evidence to suggest increased mortality with uncertain benefit for its use beyond three hours. Read their full analysis: http://www.bmj.com/content/350/bmj.h1075

NOW PLAYING

Thrombolysis in acute ischaemic stroke - time for a rethink?

0:00 16:28

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Medicine and Science from The BMJ?

This episode is 16 minutes long.

When was this Medicine and Science from The BMJ episode published?

This episode was published on March 18, 2015.

What is this episode about?

In the US the licence, or marketing authorisation, for alteplase is limited to 0-3 hours after onset of stroke, but some other countries - including the UK and Australia - have extended the licence to 4.5 hours. In an analysis article on thebmj.com...

Can I download this Medicine and Science from The BMJ episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!